Safety of Pandemic (H1N1) 2009 Monovalent Vaccines in Taiwan: A Self-Controlled Case Series Study

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Huang, Wan Ting ^a   Yang, Hsu Wen ^a   Liao, Tzu Lin ^a   Wu, Wan Jen ^a   Yang, Shu Er ^a   Chih, Yi Chien ^a   Chuang, Jen Hsiang ^a  

^a CENTER FOR DISEASE CONTROL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; MIFAMURTIDE;

2009 H1N1 INFLUENZA; ADOLESCENT; ADULT; ADVERSE EVENTS OF SPECIAL INTEREST; AGE; ANALYTIC METHOD; ARTICLE; BELL PALSY; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CHILD; CONTROLLED STUDY; CONVULSION; DEMYELINATING NEUROPATHY; DRUG DATABASE; DRUG INDUCED DISEASE; DRUG SAFETY; ENCEPHALITIS; GUILLAIN BARRE SYNDROME; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INCIDENCE; INFANT; INFLUENZA VACCINATION; MYELITIS; PRESCHOOL CHILD; RISK ASSESSMENT; SCHOOL CHILD; SELF CONTROLLED CASE SERIES METHOD; TAIWAN; VACCINATION REACTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; GUILLAIN-BARRE SYNDROME; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; RISK; TAIWAN; YOUNG ADULT;

EID: 84874900226     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058827     Document Type: Article

References (36)

1. World Health Organization (2009) New influenza A (H1N1) virus: global epidemiological situation, June 2009. Wkly Epidemiol Rec 84: 249-257.
2. Huang WT, Chen WW, Yang HW, Chen WC, Chao YN, et al. (2010) Design of a robust infrastructure to monitor the safety of the pandemic A(H1N1) 2009 vaccination program in Taiwan. Vaccine 28: 7161-7166.
3. Vellozzi C, Burwen DR, Dobardzic A, Ball R, Walton K, et al. (2009) Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. Vaccine 27: 2114-2120.
4. McMahon AW, Iskander J, Haber P, Chang S, Woo EJ, et al. (2005) Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the Vaccine Adverse Event Reporting System, 1990-2003. Pediatrics 115: 453-460.
5. Hambridge S, Glanz J, France E, McClure D, Xu S, et al. (2006) Safety of trivalent inactivated influenza vaccine in children 6-23 months old. JAMA 296: 1990-1997.
6. Greene SK, Kulldorff M, Lewis EM, Li R, Yin R, et al. (2010) Near realtime surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project. Am J Epidemiol 171: 177-188.
7. Kung HC, Huang KC, Kao TM, Lee YC, Chang FY, et al. (2010) A clinical study to assess the immunogenicity and safety of a monovalent 2009 influenza A (H1N1) vaccine in an area with low-level epidemics of pandemic influenza. Vaccine 28: 7337-7343.
8. Lu CY, Shao PL, Chang LY, Huang YC, Chiu CH, et al. (2010) Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents. Vaccine 28: 5864-5870.
9. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, et al. (2009) Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. New Engl J Med 361: 2424-2435.
10. Schonberger LB, Bregman DJ, Sullivan-Bolyai JE, Keenlyside RA, Ziegler DW, et al. (1979) Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol 110: 105-123.
11. Whitaker HJ, Farrington CP, Spiessens B, Musonda P, (2006) Tutorial in biostatistics: the self-controlled case series method. Stat Med 25: 1768-1797.
12. Jackson ML, Nelson JC, Weiss NS, Neuzil KM, Barlow W, et al. (2008) Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study. Lancet 372: 398-405.
13. Bureau of National Health Insurance, National Health Insurance in Taiwan 2011 Annual Report. Available: http://www.nhi.gov.tw/Resource/webdata/13767_1_NHI%20IN%20TAIWAN%202011%20ANNUAL%20REPORT.pdf. Accessed 17 September 2012.
14. Black S, Eskola J, Siegrist CA, Halsey N, MacDonald N, et al. (2009) Importance of background rates of disease in assessment of vaccine safety during mass immunization with pandemic H1N1 influenza vaccines. Lancet 374: 2115-2122.
15. Lasky T, Terracciano GJ, Magder L, Koski CL, Ballesteros M, et al. (1998) The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 339: 1797-1802.
16. Zhou W, Pool V, DeStefano F, Iskander JK, Haber P, et al. (2004) A potential signal of Bell's palsy after parenteral inactivated influenza vaccines: reports to the Vaccine Adverse Event Reporting System (VAERS) - United States, 1991-2001. Pharmacoepidemiol Drug Saf 13: 505-510.
17. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, et al. (2004) Risk of myocardial infarction and stroke after acute infection or vaccination. New Engl J Med 351: 2611-2618.
18. Glanz JM, McClure DL, Xu S, Hambidge SJ, Lee M, et al. (2006) Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations. J Clin Epidemiol 59: 808-818.
19. Tokars JI, Lewis P, DeStefano F, Wise M, Viray M, et al. (2012) The risk of Guillain-Barré syndrome associated with influenza A (H1N1) 2009 monovalent vaccine and 2009-2010 seasonal influenza vaccines: results from self-controlled analyses. Pharmacoepidemiol Drug Saf 21: 546-552.
20. Greene SK, Rett M, Weintraub ES, Li L, Yin R, et al. (2012) Risk of confirmed Guillain-Barré syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink Project, 2009-2010. Am J Epidemiol 175: 1100-1109.
21. Wise ME, Viray M, Sejvar JJ, Lewis P, Baughman AL, et al. (2012) Guillain-Barré syndrome during the 2009-2010 H1N1 influenza vaccination campaign: population-based surveillance among 45 million Americans. Am J Epidemiol 175: 1110-1119.
22. Yih WK, Lee GM, Lieu TA, Ball R, Kulldorff M, et al. (2012) Surveillance for adverse events following receipt of pandemic 2009 H1N1 vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System, 2009-2010. Am J Epidemiol 175: 1120-1128.
23. De Wals P, Deceuninck G, Toth E, Boulianne N, Brunet D, et al. (2012) Risk of Guillain-Barré syndrome following H1N1 influenza vaccination in Quebec. JAMA 308: 175-81.
24. Stowe J, Andrews N, Wise L, Miller E, (2009) Investigation of the temporal association of Guillain-Barré syndrome with influenza vaccine and influenza-like illness using the United Kingdom General Practice Research Database. Am J Epidemiol 169: 382-388.
25. Grimaldi-Bensouda L, Alperovitch A, Besson G, Vial C, Cuisset GM, et al. (2011) Guillain-Barré syndrome, influenza-like illness, and influenza vaccination during seasons with and without circulating A/H1N1 viruses. Am J Epidemiol 174: 326-335.
26. Dieleman J, Romio S, Johansen K, Weibel D, Bonhoeffer J, et al. (2011) Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe. BMJ 343: d3908 DOI: 10.1136/bmj.d3908.
27. Chuang JH, Huang AS, Huang WT, Liu MT, Chou JH, et al. (2012) Nationwide surveillance of influenza during the pandemic (2009-10) and postpandemic (2010-11) periods in Taiwan. PLoS One 7: e36120.
28. Huang WT, Huang WI, Huang YW, Hsu CW, Chuang JH, (2012) The reporting completeness of a passive safety surveillance system for pandemic (H1N1) 2009 vaccines: a capture-recapture analysis. Vaccine 30: 2168-2172.
29. Campbell KE, Brundage JF, (2002) Effects of climate, latitude, and season on the incidence of Bell's palsy in the US Armed Forces, October 1998 to September 1999. Am J Epidemiol 156: 32-39.
30. Lee GM, Greene SK, Weintraub ES, Baggs J, Kulldorff M, et al. (2011) H1N1 and seasonal influenza vaccine safety in the Vaccine Safety Datalink project. Am J Prev Med 41: 121-128.
31. Bardage C, Persson I, Ortqvist A, Bergman U, Ludvigsson JF, et al. (2011) Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden. BMJ 343: d5956 DOI: 10.1136/bmj.d5956.
32. Glaser CA, Winter K, DuBray K, Harriman K, Uyeki TM, et al. (2012) A population-based study of neurologic manifestations of severe influenza A(H1N1)pdm09 in California. Clin Infect Dis 55: 514-520.
33. Fine PEM, Chen RT, (1992) Confounding in studies of adverse reactions to vaccines. Am J Epidemiol 136: 121-135.
34. Rowhani-Rahbar A, Klein NP, Dekker CL, Edwards KM, Marchant CD, et al. (2012) Biologically plausible and evidence-based risk intervals in immunization safety research. Vaccine. In press. DOI: 10.1016/j.vaccine.2012.07.024.
35. Farrington P, Pugh S, Colville A, Flower A, Nash J, et al. (1995) A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 345: 567-569.
36. Tse A, Tseng HF, Greene SK, Vellozi C, Lee GM, et al. (2012) Signal detection and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011. Vaccine 30: 2024-2031.